SF3B1 and glioblastoma: All these data demonstrate that changes in the splicing of BCL2L1 seem to be one of the main molecular mechanisms underlying the link between SF3B1 blockade and the significant decrease in GBM onset, GBM progression, and aggressiveness features observed in response to pladienolide B treatment.